GlassScriptPhysician profile
Roberto Montoya
NPI 1174517254
$2,009.61
in general payments reported to CMS, 2019-2025
13 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $48.08 · 2021: $390 · 2022: $160 · 2023: $537 · 2024: $285 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $514.87 | 2019-2022 | |
| Asd Specialty Healthcare, LLC | $328.88 | 2021-2025 | |
| Abbvie INC. | $278.27 | 2023-2025 | |
| Mentor Worldwide LLC | $144.77 | 2023 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Kerecis Limited | $135.12 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Motiva USA, LLC | $134.15 | 2024 | |
| Ethicon US, LLC | $116.42 | 2024 | Surgicel Nu-Knit, Dermabond, Stratafix |
| Depuy Synthes Sales INC. | $112.51 | 2023 | Matrixmandible |
| Astellas Pharma US INC | $68.01 | 2024-2025 | Xospata, Vyloy |
| Beigene USA, INC. | $58.39 | 2023-2025 | Tevimbra, Brukinsa |
| G1 Therapeutics, INC. | $56.50 | 2023 | Cosela |
| Axogen | $48.08 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.64 | 2025 | Tagrisso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Montoya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.